Immunotherapy of Cancer: Reprogramming Tumor-Immune Crosstalk

Article, Review English OPEN
Payne, Kyle K. ; Toor, Amir A. ; Wang, Xiang-Yang ; Manjili, Masoud H. (2012)
  • Publisher: Hindawi Publishing Corporation
  • Journal: Clinical and Developmental Immunology, volume 2,012 (issn: 1740-2522, eissn: 1740-2530)
  • Related identifiers: doi: 10.1155/2012/760965, pmc: PMC3477552
  • Subject: Review Article | RC581-607 | Immunologic diseases. Allergy | Article Subject
    mesheuropmc: chemical and pharmacologic phenomena

The advancement of cancer immunotherapy faces barriers which limit its efficacy. These include weak immunogenicity of the tumor, as well as immunosuppressive mechanisms which prevent effective antitumor immune responses. Recent studies suggest that aberrant expression of cancer testis antigens (CTAs) can generate robust antitumor immune responses, which implicates CTAs as potential targets for immunotherapy. However, the heterogeneity of tumor cells in the presence and quantity of CTA expression results in tumor escape from CTA-specific immune responses. Thus, the ability to modulate the tumor cell epigenome to homogenously induce expression of such antigens will likely render the tumor more immunogenic. Additionally, emerging studies suggest that suppression of antitumor immune responses may be overcome by reprogramming innate and adaptive immune cells. Therefore, this paper discusses recent studies which address barriers to successful cancer immunotherapy and proposes a strategy of modulation of tumor-immune cell crosstalk to improve responses in carcinoma patients.
  • References (87)
    87 references, page 1 of 9

    Cobleigh, M. A.. Other options in the treatment of advanced breast cancer. Seminars in Oncology. 2011; 38: S11-S16

    Johnston, S. R.. The role of chemotherapy and targeted agents in patients with metastatic breast cancer. European Journal of Cancer. 2011; 47: S38-S47

    Berry, J.. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer. Clinical Therapeutics. 2005; 27 (11): 1671-1684

    Markopoulos, C. J.. Minimizing early relapse and maximizing treatment outcomes in hormone-sensitive postmenopausal breast cancer: efficacy review of AI trials. Cancer and Metastasis Reviews. 2010; 29 (4): 581-594

    Brewster, A. M., Hortobagyi, G. N., Broglio, K. R., Kau, S. W., Santa-Maria, C. A., Arun, B., Buzdar, A. U., Booser, D. J., Valero, V., Bondy, M., Esteva, F. J.. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. Journal of the National Cancer Institute. 2008; 100 (16): 1179-1183

    Benson, J. R., Jatoi, I., Keisch, M., Esteva, F. J., Makris, A., Jordan, V. C.. Early breast cancer. The Lancet. 2009; 373 (9673): 1463-1479

    Curigliano, G., Spitaleri, G., Petri, E., Rescigno, M., de Braud, F., Cardillo, A., Munzone, E., Rocca, A., Bonizzi, G., Brichard, V., Orlando, L., Goldhirsch, A.. Breast cancer vaccines: a clinical reality or fairy tale?. Annals of Oncology. 2006; 17 (5): 750-762

    Zhou, J., Zhong, Y.. Breast cancer immunotherapy. Cellular & Molecular Immunology. 2004; 1 (4): 247-255

    Ladjemi, M. Z., Jacot, W., Chardès, T., Pèlegrin, A., Navarro-Teulon, I.. Anti-HER2 vaccines: new prospects for breast cancer therapy. Cancer Immunology, Immunotherapy. 2010; 59 (9): 1295-1312

    Chapuis, A. G., Thompson, J. A., Margolin, K. A.. Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109 (12): 4592-4597

  • Related Research Results (1)
  • Metrics
    No metrics available
Share - Bookmark